Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib 50 mg vs 100 mg in Early Chronic Phase CML
NCT03625388Phase 2Completed
- Sponsor
- Hikma Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Jul 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of dasatinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Hikma Pharmaceuticals. Primary endpoint: Major Molecular Response at 12 months. Started Nov 2018; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03625388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625388.